King Faisal Specialist Hospital and Research Centre Showcases its Health Innovations and Solutions at the Global Health Exhibition
RIYADH, Saudi Arabia, Oct. 28, 2023 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is participating as a strategic health partner in the Global Health Exhibition 2023, which begins in Riyadh tomorrow and continues for three days.
The hospital, through its pavilion participating in the exhibition accompanying the forum, will showcase its most prominent innovations and health solutions within the framework of its strategic directions aimed at strengthening its position as a pioneer of knowledge through education, research, innovation, and providing health care with the highest levels of quality and safety.
His Excellency the CEO of King Faisal Specialist Hospital and Research Centre, Dr. Majid Ibrahim Al Fayyadh, stated on this occasion: The Kingdom of Saudi Arabia is working to consolidate its position as a global leader in the field of innovation, fostering a dynamic ecosystem that embraces the latest technologies, supporting the future of healthcare, and establishing it as a worldwide destination.
Dr Majid Ibrahim Al Fayyadh stressed that KFSH&RC’s participation in the exhibition comes in the context of its commitment to advancing innovation in the health sector from the national to the global level and supporting everything that contributes to providing the highest levels of healthcare and the best patient experience.
KFSH&RC introduces visitors of the exhibition to its various health innovations and solutions and their impact on enhancing health care outcomes and patient experience and improving operating efficiency in multiple medical fields, including the patient journey, space biomedical research, genomic medicine, capacity management, radiopharmaceutical drug production, and treatment, with T cells (CAR-T Cell).
KFSH&RC is poised to exhibit its innovations, demonstrating its leadership in biomedical space research. This is underscored by its leadership in overseeing four research experiments in cell sciences conducted in space, solidifying the hospital's pioneering role in fostering international innovation. Additionally, the hospital will present its T-cell re-engineering treatment program for cancer patients, signifying a significant enhancement in specialized medical care within the Kingdom. This advancement also translates to reduced financial and health burdens, as patients are no longer required to seek treatment abroad.
KFSH&RC is considered among the most prominent in the world in providing specialized health care, a pioneer in innovation, and an advanced medical research and education center. It also seeks to develop medical technologies and raise health care worldwide in partnership with major local, regional, and international institutions, to achieve world-class service in the clinical, research, and educational fields.
Contact information:
kfshrc@mcsaatchi.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b3530bb-ea2d-42ee-a358-4c2fe3f8630e
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w
The notes bought back by Municipality Finance will be removed from trading at Nasdaq Helsinki29.11.2023 10:00:00 CET | Press release
Municipality Finance Plc Stock exchange release 29 November 2023 at 11:00 am (EET) The notes bought back by Municipality Finance will be removed from trading at Nasdaq Helsinki On 27 November 2023 Municipality Finance Plc announced that it has bought back its EUR 10 million notes (ISIN XS2485560481) in whole. Nasdaq Helsinki has today approved MuniFin’s application to remove the notes from trading. MUNICIPALITY FINANCE PLC Further information: Joakim Holmström Executive Vice President, Capital Markets and Sustainability tel. +358 50 444 3638 MuniFin (Municipality Finance Plc) is one of Finland’s largest credit institutions. The owners of the company include Finnish municipalities, the public sector pension fund Keva and the Republic of Finland. MuniFin Group also includes the subsidiary company, Financial Advisory Services Inspira Ltd. The Group’s balance sheet totals approximately EUR 48 billion. MuniFin builds a better and more sustainable future with its customers. Our customers inc
Investeringsforeningen PortfolioManager - anmodning om suspension i afdeling29.11.2023 09:44:09 CET | pressemeddelelse
Pga. tekniske udfordringer har Investeringsforeningen PortfolioManager anmodet om suspension med handel af følgende afdelinger/andelsklasser: Afdelinger/andelsklasser i Investeringsforeningen PortfolioManagerFondskodeShortnameAI Alpha Lab Globale Aktier, kl nDK0062612644PMIAAN Suspensionen vil blive ophævet, når de tekniske udfordringer er løst, og det igen er muligt at stille priser. Eventuel henvendelse vedrørende denne meddelelse kan rettes til undertegnede på tlf. 38 42 21 42. Med venlig hilsen Nina Trolle Boldt, adm. direktør Fundmarket A/S
Buy-backs of shares in CoinShares International Limited29.11.2023 09:00:00 CET | Press release
29 November 2023 | SAINT HELIER, Jersey - As announced on 07 November 2023, the Board of Directors of CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), Europe's leading alternative asset manager specialising in digital assets, resolved to extend a share buy-back program and repurchase shares on Nasdaq Stockholm Market during the period 07 November 2023, up to and including 30 May 2024 for total maximum amount of SEK 30 million in accordance with the authorisation from the Annual General Meeting on 31 May 2023. The Board of Directors’ resolution to implement the share buy-back program was made after the Board's review of the Company's capital structure and was implemented for the purposes of reducing the capital of the Company. The share buy-back program is carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulatio
Deutsche Digital Assets Wins Pension Fund as Anchor Investor for DDA Crypto Select 10 ETP (SLCT)29.11.2023 09:00:00 CET | Press release
Institutional anchor investor for DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0; WKN: A3G3ZD, Ticker: SLCT) The DDA Crypto Select 10 ETP reflects the MarketVector™ Digital Assets Max 10 VWAP Close Index (“MVDAMV”)With the ETP, investors are in a position to affordably gain exposure to a basket collection of (up to) the 10 most important crypto assetsThe ETP is 100% collateralized by coins held in an institutional custody solution FRANKFURT, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Deutsche Digital Assets GmbH has gained a renowned institutional anchor investor for the DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0 | WKN: A3G3ZD), which was launched in June 2023. DDA prevailed against the competition in a selection process and was commissioned to design a crypto ETP that meets high quality standards and strict requirements of an institutional investor. After several months of preparation, this investment product can now be administered by a leading capital management company acting on be